FDA Approves Brentuximab Vedotin for the Treatment of Adult Patients with Primary Cutaneous Anaplastic Large Cell Lymphoma
Nov 08
2017
The Food and Drug Administration granted regular approval to brentuximab vedotin (ADCETRIS, Seattle Genetics, Inc.) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
